The stock of Silexion Therapeutics Corp (SLXN) has seen a -7.30% decrease in the past week, with a 0.00% drop in the past month, and a -63.51% decrease in the past quarter. The volatility ratio for the week is 10.72%, and the volatility levels for the past 30 days are at 18.10% for SLXN. The simple moving average for the last 20 days is 10.04% for SLXN stock, with a simple moving average of -95.90% for the last 200 days.
Is It Worth Investing in Silexion Therapeutics Corp (NASDAQ: SLXN) Right Now?
The 36-month beta value for SLXN is also noteworthy at -0.06. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SLXN is 7.65M, and at present, short sellers hold a 12.76% of that float. The average trading volume of SLXN on March 17, 2025 was 14.23M shares.
SLXN) stock’s latest price update
The stock price of Silexion Therapeutics Corp (NASDAQ: SLXN) has plunged by -3.05 when compared to previous closing price of 1.31, but the company has seen a -7.30% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-03-17 that NEW YORK–(BUSINESS WIRE)—- $SLXN #biotech–PESG Research releases a report covering Silexion Therapeutics’ (NASDAQ: SLXN)* latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology’s most challenging targets. The.
SLXN Trading at -6.06% from the 50-Day Moving Average
After a stumble in the market that brought SLXN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.96% of loss for the given period.
Volatility was left at 18.10%, however, over the last 30 days, the volatility rate increased by 10.72%, as shares surge +15.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.69% lower at present.
During the last 5 trading sessions, SLXN fell by -8.58%, in comparison to the 20-day moving average, which settled at $1.1532. In addition, Silexion Therapeutics Corp saw -36.82% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLXN
The total capital return value is set at 25.0. Equity return is now at value -3.78, with -284.50 for asset returns.
Based on Silexion Therapeutics Corp (SLXN), the company’s capital structure generated -16.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.56. The debt to equity ratio resting at -0.94. The interest coverage ratio of the stock is 302.41.
Currently, EBITDA for the company is -4.64 million with net debt to EBITDA at -0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.85.
Conclusion
In summary, Silexion Therapeutics Corp (SLXN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
